Detailed performance report for BRAINSWAY covering Q3 2025. Gain clarity on earnings, revenue trends, and AI-enhanced strategic analysis.
Summary of Financial Performance: BrainsWay reported record quarterly revenue of $13.5 million for Q3 2025, a 29% increase from the previous year. The company shipped 90 Deep TMS systems, a 43% increase year-over-year, with a total installed base now exceeding 1,600 systems globally. Gross profit was $10.2 million with a strong gross margin of 75%. Operating profit increased to $1.3 million from $0.3 million the previous year, and net profit rose to $1.6 million from $0.7 million in 2024. The company ended the quarter with $70.7 million in cash and cash equivalents, maintaining a debt-free capital structure.
Company Outlook & Strategy: BrainsWay raised its full-year 2025 revenue guidance to $51-$52 million and expects operating profit margins of 6%-7% and adjusted EBITDA margins of 13%-14%. The company continues to focus on selling to large enterprise customers through multiyear lease agreements, which have resulted in high customer retention and scalability. Strategic pillars include elevating market awareness, advancing R&D for new treatment indications, and expanding global patient access.
Key Industry Trends: The company noted increasing demand for its Deep TMS systems and highlighted the potential of an accelerated protocol for major depressive disorder (MDD) recently approved by the FDA. This development is expected to improve treatment convenience and appeal to more patients.
Operational Highlights: BrainsWay is investing in minority stakes in mental health providers and complementary enterprises to expand its market presence without deviating from its core focus on Deep TMS. Recent investments include Neurolief LTD, with plans for further strategic partnerships in the coming quarters.
Challenges & Risks: Potential delays in FDA clearances could impact product distribution timelines, as noted with Neurolief’s anticipated approval. Additionally, geopolitical and supply chain issues present broader risks.
Key Analyst Questions & Responses: Analysts inquired about the accelerated protocol's adoption and future minority equity investments. The company expects increased demand due to the accelerated protocol and plans to finalize at least one more minority investment by year-end. Questions also focused on the potential revenue impact of these investments, which currently do not contribute to top-line figures but are accounted for under operating profit. The company emphasized its ongoing international expansion efforts, particularly in Asia Pacific and Europe.
Access the official earnings call transcript for BRAINSWAY 2025 Q3. It provides valuable insights into management commentary, performance drivers, and forward-looking guidance directly from the company.